Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund
Rhea-AI Filing Summary
Imunon, Inc. is reported to have 450,315 shares of its common stock beneficially owned by Armistice Capital, LLC and Steven Boyd, who together are the reporting persons. This represents 9.99% of Imunon’s outstanding common stock.
Armistice Capital is the investment manager of Armistice Capital Master Fund Ltd., the direct holder of the shares, and exercises voting and investment power over these securities under an Investment Management Agreement. Steven Boyd, as managing member of Armistice Capital, may be deemed to share beneficial ownership. The Master Fund has the right to receive dividends and sale proceeds for the reported securities.
Positive
- None.
Negative
- None.
Key Figures
Beneficially owned shares: 450,315 shares
Percent of class: 9.99%
Shared voting power: 450,315 shares
+2 more
5 metrics
Beneficially owned shares
450,315 shares
Imunon common stock beneficially owned by Armistice Capital and Steven Boyd
Percent of class
9.99%
Portion of Imunon common stock reported as beneficially owned
Shared voting power
450,315 shares
Shares over which the reporting persons have shared power to vote or direct the vote
Shared dispositive power
450,315 shares
Shares over which the reporting persons have shared power to dispose or direct disposition
Sole voting power
0 shares
Shares with sole voting power reported by the reporting persons
Key Terms
beneficially own, shared voting power, shared dispositive power, Investment Management Agreement, +1 more
5 terms
beneficially own financial
"may be deemed to beneficially own the securities of the Issuer held"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Investment Management Agreement financial
"pursuant to an Investment Management Agreement, Armistice Capital exercises"
An investment management agreement is a written contract that hires a professional to make buying, selling and strategy decisions for an investment account or fund, and sets out their duties, fees, risk limits, performance measures and reporting requirements. It matters to investors because the agreement determines who controls the money, how much the service costs, what risks are allowed, and how success or failure is measured—think of it as the service contract that defines expectations and remedies for a hired portfolio manager.
exempted company financial
"The Master Fund, a Cayman Islands exempted company that is an investment"
FAQ
How much of Imunon, Inc. (IMNN) does Armistice Capital report owning?
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 450,315 shares of Imunon common stock, representing 9.99% of the outstanding class, held through Armistice Capital Master Fund Ltd.
Who are the reporting persons in the Imunon (IMNN) Schedule 13G/A?
The reporting persons are Armistice Capital, LLC and Steven Boyd. Armistice Capital is investment manager to Armistice Capital Master Fund Ltd., and Boyd is its managing member, so each may be deemed to beneficially own the fund’s Imunon shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.